Gold Bamboo
🩺 Conditions 💊 Medications 🌿 Supplements 🧘 Modalities ⚕️ Treatments 🔬 Tests 🥗 Diets 🫀 Body Systems
Browse all health topics
Supplements East vs West Relates Health AI Practitioners List your practice Search
Login

Chemotherapy-induced nausea and vomiting (CINV)

Moderate Evidence

Overview

Chemotherapy-induced nausea and vomiting (CINV) refers to nausea, retching, and vomiting that occur as a result of cancer treatment with chemotherapy drugs. It is one of the most recognized and historically feared side effects of cancer care because it can substantially affect quality of life, nutritional intake, hydration, sleep, emotional well-being, and a person’s willingness to continue treatment. Although modern antiemetic strategies have greatly reduced severe vomiting in many settings, nausea remains difficult to control for some patients, and breakthrough symptoms still occur.

CINV is commonly divided into several clinical patterns. Acute CINV occurs within the first 24 hours after chemotherapy, while delayed CINV appears more than 24 hours later and may last several days. Anticipatory CINV can develop before treatment in people who have previously experienced poorly controlled symptoms, reflecting a learned or conditioned response. Clinicians may also describe breakthrough CINV when symptoms occur despite preventive treatment, and refractory CINV when symptoms continue in subsequent cycles after earlier antiemetic strategies were unsuccessful.

Risk depends on both the emetogenic potential of the chemotherapy regimen and individual patient factors. Some agents, such as cisplatin and certain anthracycline-based combinations, are considered highly emetogenic, while others carry moderate, low, or minimal risk. Studies also indicate that younger age, female sex, low habitual alcohol intake, motion sickness history, prior pregnancy-related nausea, anxiety, and earlier poor symptom control may increase susceptibility. Importantly, nausea and vomiting in a person undergoing cancer treatment can also have causes other than chemotherapy, including bowel obstruction, brain metastases, infection, pain, electrolyte abnormalities, opioid use, or radiation therapy, so symptom evaluation is clinically important.

From a broader health perspective, CINV is significant because uncontrolled symptoms can contribute to dehydration, malnutrition, weight loss, treatment delays, and reduced adherence to cancer therapy. For this reason, CINV is usually approached proactively rather than reactively in modern oncology. Integrative cancer care programs often discuss both conventional antiemetic medications and supportive modalities such as acupuncture, acupressure, mind-body practices, dietary adjustment, and traditional herbal frameworks, with the understanding that evidence quality varies and safety considerations are especially important during active cancer treatment.

Western Medicine Perspective

Western / Conventional Medicine Perspective

In conventional oncology, CINV is understood primarily through neurochemical pathways involving the central nervous system and gastrointestinal tract. Chemotherapy can trigger release of serotonin (5-HT) from enterochromaffin cells in the gut, activate vagal afferents, and stimulate brainstem emetic centers. Other mediators, including substance P acting at neurokinin-1 (NK1) receptors and dopamine signaling, also play important roles, particularly in delayed symptoms. This mechanistic understanding has led to preventive antiemetic regimens tailored to the emetogenicity of a chemotherapy regimen.

Current guidelines from major oncology organizations commonly stratify prevention by risk category. For highly emetogenic chemotherapy, multi-drug prophylaxis often includes a 5-HT3 receptor antagonist, an NK1 receptor antagonist, and dexamethasone, with olanzapine frequently incorporated in many modern protocols. Moderate-risk regimens may use similar but somewhat simplified approaches depending on the specific drugs involved. The emphasis in conventional care is on prevention before chemotherapy begins, because once severe nausea and vomiting become established they are often harder to control. Ongoing assessment also distinguishes acute, delayed, anticipatory, and breakthrough patterns so that supportive care can be adjusted cycle to cycle.

Conventional medicine also recognizes that nausea is often more difficult to suppress than vomiting, and that patient-reported outcomes matter. Research supports the value of standardized antiemetic guidelines from groups such as ASCO, NCCN, and MASCC/ESMO, yet underuse or inconsistent use of guideline-based prophylaxis still occurs in practice. In addition, not all nausea during chemotherapy is classic CINV; clinicians may evaluate for other medical causes, medication effects, constipation, metabolic abnormalities, vestibular triggers, or disease progression. Consultation with the oncology team is important when symptoms are severe, persistent, or atypical.

Eastern & Traditional Perspective

Eastern / Traditional Medicine Perspective

In Traditional Chinese Medicine (TCM), nausea and vomiting during chemotherapy may be interpreted through patterns such as rebellious Stomach qi, Spleen qi deficiency, phlegm-damp accumulation, or disharmony between the Liver and Stomach. Within this framework, treatment principles traditionally aim to harmonize the middle burner, redirect qi downward, strengthen digestive function, and calm the spirit. Commonly discussed modalities include acupuncture, acupressure, moxibustion, and individualized herbal formulas. Among these, stimulation of P6 (Neiguan) is one of the best-known traditional approaches for nausea and has also been studied in supportive oncology settings.

From an Ayurvedic perspective, chemotherapy-related digestive distress may be described in terms of disturbed agni (digestive fire), aggravated vata and pitta, and depletion associated with intensive illness and treatment. Traditional management may emphasize gentle digestive support, calming practices, rest, and constitution-based herbal or dietary approaches. In naturopathic and integrative oncology settings, ginger, mind-body therapies, hydration-focused dietary strategies, and acupressure are often discussed as adjunctive supports, though practitioners generally note the need for caution around herb-drug interactions, immunosuppression, mucosal irritation, and variability in supplement quality.

The evidence base is strongest for acupuncture/acupressure as adjunctive symptom support, especially for nausea, though findings are mixed across studies and protocols. Research on herbal medicine is more limited and complicated by issues of standardization, safety, and interaction potential during active chemotherapy. Traditional systems tend to view CINV not only as a gastrointestinal symptom but as a broader disturbance affecting energy, appetite, emotional state, and recovery capacity. In integrative care, these approaches are generally framed as complementary rather than substitutive, and coordination with oncology clinicians is an important safety consideration.

Related Topics

Acupuncture

Acupuncture — a modality in the health ontology.

How They Relate

Evidence & Sources

Moderate Evidence

Promising research with growing clinical support from multiple studies

  1. American Society of Clinical Oncology (ASCO) Antiemetic Guidelines
  2. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology: Antiemesis
  3. MASCC/ESMO Antiemetic Guidelines
  4. National Cancer Institute (NCI) PDQ: Nausea and Vomiting Related to Cancer Treatment
  5. National Center for Complementary and Integrative Health (NCCIH) – Acupuncture
  6. Cochrane Database of Systematic Reviews – Interventions for nausea and vomiting in people receiving chemotherapy
  7. Journal of Clinical Oncology
  8. Annals of Oncology

This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any supplement or medication regimen.